The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11022 malaria professionals are enjoying the free benefits of MalariaWorld today

controlled human malaria infection

NOT Open Access | Safety, pharmacokinetics and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study

July 13, 2020 - 16:22 -- NOT Open Access
Author(s): 
Kublin JG, Murphy SC, Prince WT, et al.
Reference: 
Clin Infect Dis. 2020 Jul 9:ciaa952

KAF156 is a novel antimalarial drug that is active against both liver- and blood- stage Plasmodium parasites, including drug-resistant strains. Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model.

Deliberately infecting healthy volunteers with malaria parasites: Perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study

July 13, 2020 - 16:19 -- Open Access
Author(s): 
Jao I, Marsh V, Che Chi P, Kapulu M, Hamaluba M, Molyneux S, Bejon P, Kamuya D
Reference: 
Bioethics. 2020 Jul 9

Controlled human malaria infection (CHMI) studies involve the deliberate infection of healthy volunteers with malaria parasites under controlled conditions to study immune responses and/or test drug or vaccine efficacy. An empirical ethics study was embedded in a CHMI study at a Kenyan research programme to explore stakeholders’ perceptions and experiences of deliberate infection and moral implications of these.

Subscribe to RSS - controlled human malaria infection